600079 ST人福医药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入12,060,702-0.03%23,962,01025,435,48424,524,74122,337,719
减:营业总成本10,131,290-1.61%20,643,68722,665,86821,417,05919,851,775
    其中:营业成本6,011,902-3.83%12,409,03614,103,26113,290,99212,615,138
               财务费用211,10874.70%303,146350,704304,519236,944
               资产减值损失(15,397)-14.81%(420,167)(393,861)(61,407)(88,312)
公允价值变动收益(1,334)-17.54%11,824112,717136,85543,417
投资收益39,929-15.70%101,039133,086206,785835,557
    其中:对联营企业和合营企业的投资收益41,0980.92%106,61368,16159,99222,514
营业利润2,018,67710.04%3,197,8652,522,0293,447,1743,516,028
利润总额1,996,38011.58%3,056,4612,422,8303,383,8293,426,053
减:所得税费用304,8164.37%564,005644,487568,563354,751
净利润1,691,56512.98%2,492,4561,778,3432,815,2663,071,302
减:非控股权益362,0115.69%637,122448,598680,781587,194
股东净利润1,329,55415.15%1,855,3341,329,7452,134,4852,484,109

市场价值指针
每股收益 (元) *0.81014.08%1.1400.8201.3201.540
每股派息 (元) *----0.4800.4700.4600.160
每股净资产 (元) *11.8305.31%11.58710.79710.4419.210
审计意见 #--标准无保留意见带有强调事项段、持续经营重大不确定性段落、其他信息段落中包含其他信息未更正重大错报说明的无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容